Bharat Biotech’s Phase 3 data claims that Covaxin is 77.8 per cent effective
Bharat Biotech’s Covaxin is overall 77.8 per cent effective against Covid, the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed. The vaccine offers “65.2 per cent protection”, it said, against the rapidly emerging Delta variant. It was also found to be “93.4 per… Continue reading "Bharat Biotech’s Phase 3 data claims that Covaxin is 77.8 per cent effective"